NDATRANSDERMALSYSTEM
Approved
Mar 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
6/8 — Strong
XELSTRYM (dextroamphetamine) by Noven Pharmaceuticals is clinical pharmacology amphetamines are noncatecholamine, sympathomimetic amines with cns stimulant activity. Approved for attention deficit hyperactivity disorder. First approved in 2022.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XELSTRYM is a transdermal dextroamphetamine system approved in March 2022 for Attention Deficit Hyperactivity Disorder (ADHD). It is a CNS stimulant that elevates norepinephrine and dopamine activity through sympathomimetic mechanisms. The transdermal formulation offers an alternative delivery route to oral amphetamine products, potentially improving compliance and providing steady-state dosing.
$0.051BPart D
Peak15.7 years to LOEEarly-stage peak phase product with minimal Medicare claims volume; likely small commercial team building market presence in a crowded ADHD space.
Mechanism of Action
CLINICAL PHARMACOLOGY Amphetamines are noncatecholamine, sympathomimetic amines with CNS stimulant activity. Peripheral actions include elevations of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action. There is neither specific evidence that clearly…
Pharmacologic Class:
Central Nervous System Stimulant
Indications (1)
Worked on XELSTRYM at Noven Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.